Iterum Therapeutics (ITRM) News Today $0.99 -0.01 (-0.91%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.00 +0.01 (+0.92%) As of 06/13/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Iterum Therapeutics PLC: Iterum Therapeutics Announces Partnership for Commercialization ServicesJune 12 at 12:45 AM | finanznachrichten.deIterum Therapeutics Announces Partnership for Commercialization ServicesJune 11 at 7:00 AM | globenewswire.comIterum Therapeutics Announces Extension of Term of Promissory NoteMay 19, 2025 | globenewswire.comIterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ...May 14, 2025 | finance.yahoo.comIterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026May 13, 2025 | msn.comIterum Therapeutics plc (ITRM) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comIterum Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comA Look Ahead: Iterum Therapeutics's Earnings ForecastMay 12, 2025 | benzinga.comIterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025May 6, 2025 | globenewswire.comIterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary SharesApril 30, 2025 | globenewswire.comIterum Therapeutics plc Announces Definitive Agreement for $5 Million Registered Direct Offering of SharesApril 29, 2025 | quiverquant.comIterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary SharesApril 29, 2025 | globenewswire.comIterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of AntibioticsApril 14, 2025 | globenewswire.comShort Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Declines By 14.6%Iterum Therapeutics plc (NASDAQ:ITRM - Get Free Report) saw a large decline in short interest in February. As of February 28th, there was short interest totalling 1,580,000 shares, a decline of 14.6% from the February 13th total of 1,850,000 shares. Based on an average daily trading volume, of 783,000 shares, the days-to-cover ratio is currently 2.0 days. Currently, 4.7% of the shares of the stock are sold short.March 20, 2025 | marketbeat.comIterum Therapeutics Appoints New Board MembersMarch 10, 2025 | tipranks.comIterum Therapeutics faces Nasdaq non-compliance issueFebruary 15, 2025 | msn.comIterum Therapeutics plc (ITRM) Q4 2024 Earnings Call TranscriptFebruary 9, 2025 | seekingalpha.comIterum Therapeutics plc (NASDAQ:ITRM) Q4 2024 Earnings Call TranscriptFebruary 8, 2025 | insidermonkey.comIterum outlines ORLYNVAH's market potential with exclusivity through 2034February 8, 2025 | seekingalpha.comIterum Therapeutics files $150M mixed securities shelfFebruary 8, 2025 | markets.businessinsider.comEarnings call transcript: Iterum Therapeutics reports Q4 2024 results and stock surgesFebruary 8, 2025 | msn.comIterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 7, 2025 | globenewswire.comIterum Therapeutics Q4 2024 Earnings PreviewFebruary 6, 2025 | msn.comIterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025January 31, 2025 | globenewswire.comIterum Therapeutics Regains Full Nasdaq ComplianceNovember 21, 2024 | globenewswire.comIterum Therapeutics’ Strategic Advances with ORLYNVAH ApprovalNovember 16, 2024 | markets.businessinsider.comIterum Therapeutics plc (NASDAQ:ITRM) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comIterum Therapeutics sees cash runway into 2025November 15, 2024 | markets.businessinsider.comIterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...November 15, 2024 | finance.yahoo.comIterum Therapeutics plc (ITRM) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comIterum Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | globenewswire.comA Look at Iterum Therapeutics's Upcoming Earnings ReportNovember 13, 2024 | benzinga.comFDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic PartnershipsOctober 28, 2024 | finance.yahoo.comIterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsOctober 28, 2024 | prnewswire.comIterum Therapeutics PLC trading resumesOctober 26, 2024 | markets.businessinsider.comIterum Therapeutics announces FDA approval of OrlynvahOctober 26, 2024 | markets.businessinsider.comIterum Therapeutics Gets FDA Approval Of Orlynvah For Treatment Of Urinary Tract InfectionsOctober 26, 2024 | markets.businessinsider.comUS FDA approves Iterum's treatment for urinary infectionOctober 26, 2024 | msn.comIterum stock rallies 54% on FDA approval of Orlynvah for UTIsOctober 26, 2024 | msn.comIterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsOctober 25, 2024 | globenewswire.comIterum Therapeutics to Present Data at IDWeek 2024October 10, 2024 | globenewswire.comIterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual SummitOctober 9, 2024 | globenewswire.comBuy Rating Justified for Iterum Therapeutics Amid Anticipated FDA Approval of Sulopenem for uUTIsSeptember 11, 2024 | markets.businessinsider.comIterum Provides Update On FDA Advisory Committee Discussion Of Oral Sulopenem To Treat UUTISeptember 10, 2024 | markets.businessinsider.comIterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult WomenSeptember 10, 2024 | markets.businessinsider.comIterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment ConferenceSeptember 6, 2024 | globenewswire.comWhen Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable?August 16, 2024 | finance.yahoo.comIterum Therapeutics PLC: Iterum Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 16, 2024 | finanznachrichten.deBuy Rating Justified for Iterum Therapeutics Amid Strong Sulopenem Prospects and Upcoming FDA Advisory Committee ReviewAugust 16, 2024 | markets.businessinsider.comIterum Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | globenewswire.com Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address ITRM Media Mentions By Week ITRM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITRM News Sentiment▼0.630.88▲Average Medical News Sentiment ITRM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITRM Articles This Week▼41▲ITRM Articles Average Week Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alumis News Editas Medicine News Aclaris Therapeutics News Enanta Pharmaceuticals News Silence Therapeutics News RAPT Therapeutics News LifeVantage News Molecular Partners News SELLAS Life Sciences Group News Spero Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITRM) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s worst nightmareThe President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ITRM Stock Free ITRM Stock Alerts